title: The metabolic syndrome--what is it and how should it be managed?
abstract: Following a hypertension symposium in Portland, ME, in October 2005, a roundtable was convened to discuss the metabolic syndrome and its significance. Dr. Marvin Moser of the Yale University School of Medicine, New Haven, CT, moderated the discussion. Participating in the discussion were Dr. Bonita Falkner of the Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA; Dr. Michael A. Weber of SUNY Downstate College of Medicine, New York, NY; and Dr. Leonard Mark Keilson of the University of Vermont College of Medicine.
authors.affiliation: Yale University School of Medicine, New Haven, CT, USA. moserbp@aol.com
authors.forename: Marvin
authors.initials: M
authors.lastname: Moser
authors.forename: Bonita
authors.initials: B
authors.lastname: Falkner
authors.forename: Michael A
authors.initials: MA
authors.lastname: Weber
authors.forename: Leonard Mark
authors.initials: LM
authors.lastname: Keilson
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002995:Clofibric Acid / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D009765:Obesity / Q000150:complications; D015431:Weight Loss
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002995:Clofibric Acid; D001241:Aspirin